Key vendors to engage in distribution partnerships to keep pace with competition in the market
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five vendors for the global HPV testing market in their latest research report. This report also lists 13 other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated from only the HPV test products used for genital cancer screening such as cervical cancer.
This Technavio report, under the in-vitro diagnostics vertical, is based on the synthesis, analysis, and interpretation of information about the global HPV testing market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The global market for HPV testing is highly competitive in nature. The market is characterized by the presence of Tier 1 and Tier 2 companies as well as small companies. The presence of kit manufacturing companies in this market space is expected to fuel further competition in market over the coming years. Tier 1 and Tier 2 companies in the market are expected to leverage distribution partnerships to gain market shares during the forecast period.
“The development of mRNA HPV test is a popular trend that is revolutionizing the global HPV testing market. HPV is the causative agent for cervical cancer. As a result, companies in the market are targeting their R&D on HPV oncoproteins that interact directly or indirectly with the host genome. Recent studies are primarily focused on the identification of host genes that are up-regulated owing to HPV infection,” says Barath Palada, a lead analyst at Technavio for in-vitro diagnostics.
Top five vendors in the HPV testing market space
Abbott Laboratories
Abbott Laboratories develops RealTime High Risk HPV assay kit and systems such as m2000 RealTime system and m24sp. In July 2014, the company showcased its next-generation products in the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, Chicago, the US. The company showcased m2000 RealTime system, which performs automated infectious disease (HPV) and molecular testing.
Key products: m2000 RealTime system and RealTime High Risk HPV assay.
BD
BD engages in the development of integrated automated systems and assay kits for HPV testing. In September 2015, BD formed a collaboration with Seegene, a leader in multiplex molecular technologies and multiplex clinical molecular diagnostics, to develop multiplex real-time PCR reagents for the BD MAX system. The product can be used in molecular diagnostics.
Key products: BD Onclarity HPV assay and BD VIPER LT system.
Roche Diagnostics
Roche Diagnostics, one of the subsidiaries of F. Hoffmann-La Roche, develops systems such as cobas 4800 system and cobas HPV test for high-risk HPV genotype 12. The company works together with its subsidiary Ventana Medical Systems that develops HPV three-in-one system control slides.
Key products: Amplicor HPV test kit, cobas 4800 system, cobas HPV test, and LINEAR ARRAY HPV genotyping test.
Qiagen
Qiagen is one of the global leaders in HPV testing. The company produces molecular diagnostic kits through R&D and licensing agreements with other technology developers. The company’s digene HC2 HPV test is a gold standard to detect HPV genotypes. In February 2014, Qiagen launched careHPV test in India. It is the only molecular diagnostic test which helps to screen cervical cancer in women with a limited healthcare infrastructure.
Key products: digene HC2 HPV DNA Test, digene HC2 Sample Conversion Kit, and careHPV Test.
Hologic
Hologic was the first to introduce FDA-approved genotyping, the Cervista HPV 16/18 test, in the market. The test identifies the two most highly oncogenic and persistent high-risk HPV types, which cause 70% of all cervical cancer cases. The company offers an mRNA-based Aptima HPV assay as an advanced cervical cancer screening test.
Key products: Aptima HPV assay, Aptima HPV 16 18/45 genotype assay, and Panther system.
Other prominent vendors in this market include Arbor Vita, Breakspear Medical, Cepheid, DAAN Gene, DiaCarta, Delphi Bioscience, Fujirebio Diagnostics, Genera Biosystems, IncellDx, OralDNA Labs, Seegene, SoloPap, and Trovagene.
A more detailed analysis is available in the Technavio report, Global HPV Testing Market 2016-2020. Technavio also customizes reports by other regions and specific segments upon request.
To read more press releases- click here.
Browse related reports:
- Global Cervical Cancer Diagnostic Testing Market 2016-2020
- Global Cancer Diagnostic Devices Market 2016-2020
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
